Search alternatives:
point decrease » point increase (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
point decrease » point increase (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
-
341
-
342
-
343
-
344
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
345
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
346
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
347
-
348
-
349
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
350
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
351
-
352
-
353
-
354
-
355
-
356
Circular Dichroism spectra for WT and three rhGH variants, observed at temperatures from 20 to 92C.
Published 2023Subjects: -
357
-
358
-
359
-
360